Join the club for FREE to access the whole archive and other member benefits.

Juvenescence

Developing therapies against different aging related diseases.

Juvenescence is a bio-pharma development company developing therapies focused on allowing people worldwide to live longer, healthier lives. We have raised USD $65M to build an ecosystem and pipeline of assets targeting ageing, age-related disease and regeneration.

Visit website: https://www.juvlabs.com/

 juvlabs

 juvenescence1

 juvlabs

Details last updated 04-May-2019

Juvenescence is also referenced in the following:

BHB Therapeutics

Developing preventative medicines for age-related disease using ketone bodies

Jeff Madwed

Executive Director of Juvenescence’s JuvTherapeutics Division

Napa Therapeutics

Focused on a novel target linked to one of the fundamental processes of aging

Selah Therapeutics

Company focused on novel ketone-based therapies for the treatment of heart diseases

Juvenescence Creations

Investing in the Future of Longevity – the Ketone Chapter

10-May-2022

Juvenescence webinar about the latest research and developments on future of longevity investment

People at Juvenescence

Gregory Bailey

CEO at Juvenescence and chairman of Portage Biotech

Jim Mellon

British entrepreneur, author and philanthropist with interests across a number of industries

Alexander Pickett

Managing Director at Juvenescence

David Gill

Chief Financial Officer at Juvenescence

David Roblin

Chief Operating Officer and CEO of Therapeutics Division at Juvenescence

Colin Watts

CEO at Juvenescence Life.

Ellen Donnelly

Chief Executive Officer of the Epigenetics Division of Juvenescence Limited

Juvenescence News

Reason reports back from Age-Related Disease Therapeutics Summit 2023

Fight Aging! - 16-Jun-2023

Many people believe lots of clinical trials of novel therapeutics targeting mechanisms of aging will start up in the next few years

Read more...

Summary of Jim Mellon presentation at Longevity Med Summit

Live Forever Club - 19-May-2023

Urges individuals with resources and a desire to contribute positively to humanity to invest in the longevity industry

Read more...

AgeX credit running out with substantial doubt it can continue

FierceBiotech - 15-Aug-2022

Let's hope their research is either successful for the company or its successors

Read more...

JuvLife Division raises 3.7 million euros for making antiaging product with Chrysea

Longevity Technology - 13-Jun-2022

Metabolites induce autophagy, stimulate cellular regeneration for healthy ageing

Read more...

Selah Therapeutics launched to focus on ketone-based therapies for heart disease

Longevity Technology - 13-May-2022

Treatment options for diseases of aging - from the makers of metabolic switch

Read more...

FDA approved LyGenesis' phase 2a trials on liver failure patients

Longevity Technology - 30-Dec-2020

Raised $11M funding which goes into trials and developing functional organs

Read more...

Jim Mellon plans to take his longevity company Juvenescence public

CNBC - 29-Sep-2020

The company with $170 million private funding has invested in various life extension therapies

Read more...

Labiotech gathers feedback from European biotechs on Unity failure

Labiotech - 28-Aug-2020

General feeling that failures are bound to happen - but that their approaches can succeed

Read more...

Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd

Juvenescence - 11-Jun-2020

Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration

Read more...

Orion College ageing research receives 1 million UK pounds from Jim Mellon

Lifespan.io (LEAF) - 18-May-2020

He believes in the importance of boosting immunoresilience among elderly

Read more...

Master Investor Magazine focuses on longevity in its Autumn edition

Master Investor - 01-Nov-2019

Interesting articles and some useful investment opportunities

Read more...

A mission to change the lives of 1 billion people

Telegraph - 23-Sep-2019

Life extension technology will be expensive, so it'll create inequalities between poor, rich people

Read more...

Today's 50 year-olds may live another 100 years

Forbes - 26-Aug-2019

Good summary of some major investments in life extension companies

Read more...

Aging focused biotechs forms AI based joint venture

FierceBiotech - 14-Aug-2018

Groundbreaking research biotechs performs aging research together for longevity

Read more...

FoxBio is developing small molecule drugs to target ageing diseases

Business Wire - 12-Jul-2018

Antoxerene partners with Juvenescence to discover drugs that clear senescent cells

Read more...

UK biotech company focused on developing anti-ageing therapies

PMLiVE - 12-Jun-2018

LyGenesis seeks to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic organs

Read more...

Interview with Juvenescence author Jim Mellon

Medium - 17-May-2018

Juvenescence Ltd is making investments in the future of rejuvenation and life extension technology

Read more...

Silicon Valley and rich people invest to slow down ageing and live longer

This Is Money - 17-Mar-2018

All the money in the world to fight ageing and death

Read more...

British billionaire gambles on an anti-aging upstart

Endpoints News - 26-Jul-2017

We are at an inflection point for the treatment of aging. We can generate molecules with specifi...

Read more...
Topics mentioned on this page:
Ageing Research